 | | Vol. 5.47 – 17 December, 2021 |
| |
|
|
| Scientists explored the expression, role and mechanism of DNA damage regulated autophagy modulator 1 (DRAM1) in alcohol-related liver disease and revealed that ethanol-induced DRAM1 of hepatic cells could increase the pyruvate kinase M2 (PKM2)-enriched extracellular vesicles.
[Molecular Therapy-Nucleic Acids] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified a novel long non-coding RNA KDM4A-AS1, which was aberrantly overexpressed in hepatocellular carcinoma (HCC) tissues, associated with unfavorable clinical features and poor prognosis of patients. KDM4A-AS1 promoted HCC cell proliferation, migration, and invasion in vitro.
[Cell Death & Disease] |
|
|
|
| Investigators showed that p15INK4b-related sequence/regulation of nuclear pre-mRNA domain-containing protein 1A (RPRD1A) was highly expressed in hepatocellular carcinoma (HCC) tumors and correlated with aggressive clinicopathological features.
[Cell Death & Disease] |
|
|
|
| Scientists investigated the role of Gm15441 in the regulation of thioredoxin-interacting protein (Txnip) and liver metabolism and found that the expression levels of Gm15441 and Txnip showed a similar response pattern to metabolic signals in vivo and in vitro, but that their functions were predicted to be opposite.
[Cell & Bioscience] |
|
|
|
| Serum soluble CD137 (sCD137) is associated with inflammatory states, and positively correlated with serum tumor necrosis factor in cirrhotic hepatitis C virus patients following virus eradication.
[European Journal of Immunology] |
|
|
|
| Investigators explored the potential functions of hypoxia-induced upregulation of Fascin-1 in liver cancer and found that Fascin-1 was upregulated by hypoxia in liver cancer cell lines, elevated in liver cancer patients and correlated with larger tumor size, lymph node metastasis, distant metastasis, and shorter overall survival.
[Cell Death Discovery] |
|
|
|
| Scientists investigated the function and mechanism of LINC00667 in hepatocellular carcinoma progression. The effects of LINC00667 silencing in cell proliferation, cell migration, and cell invasion, and androgen receptor expression were determined with loss-of-function phenotypic analysis in Huh-7 and HCCLM3 cells.
[Cell Death Discovery] |
|
|
|
| Investigators explored the regulatory mechanism of circFOXM1 in hepatocellular carcinoma (HCC) proliferation and metastasis. RNA polymerase inhibitor actinomycin D and RNase R exonuclease were used to identify circFOXM1 in HCC cells.
[Scientific Reports] |
|
|
|
| Activated hepatic stellate cell cell lines were used to evaluate the effects of tenofovir disoproxil fumarate and entecavir. After treatment with each antiviral agent, cell viability, morphology, apoptotic features, autophagy and antifibrosis signaling pathways were examined.
[PLoS One] |
|
|
|
| Researchers designed a new peptide KK-64, and it showed strong cytotoxicity against liver cancer cells. To obtain the tumor targeting property, a plasmid that contains KK-64 DNA fragment and driven by hTERT promoter was constructed.
[Bioengineered] |
|
|
|
| Investigators showed accurate tracking of the aging process in hepatocytes, demonstrated attenuated epigenetic aging in muscle stem cells and tracked age dynamics in embryonic stem cells.
[Nature Aging] |
|  |
|
|
|
| Scientists discuss how hepatitis B virus (HBV) induces inflammation and the extrahepatic manifestations of HBV infection to guide clinical management.
[American Journal of Gastroenterology] |
|
|
|
| The authors review the current knowledge on miR-27, miR-24, and miR-23 in non-alcoholic fatty liver disease (NAFLD) pathogenesis and discuss their potential significance in NAFLD diagnosis and therapy.
[Acta Pharmacologica Sinica] |
|
|
|
|
| Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus infection.
[Antios Therapeutics, Inc.] |
|
|
|
| Aligos Therapeutics, Inc. announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 evaluating ALG-055009 for the treatment of nonalcoholic steatohepatitis (NASH).
[Aligos Therapeutics, Inc. (Globe Newswire, Inc.)] |
|
|
|
|
| February 5 – 9, 2022
Maui, Hawaii, United States |
|
|
|
|
|
| | University of Southern Denmark – Odense M, Denmark |
|
|
|
| | National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
| | University of Gothenburg РG̦teborg, Sweden |
|
|
|
| | Accession Therapeutics – Oxford, England, United Kingdom |
|
|
|
| | KU Leuven – Leuven, Belgium |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
